Rodin Chermat

Rodin Chermat

Auto-generated profile, based on publicly available information

Rodin Chermat

μFO Lab, Institute of Biomedical Engineering, Polytechnique Montréal, Montréal, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
RCRodin Chermat
Rodin Chermat
ERElena Refet-Mollof
Elena Refet-Mollof
YKYuji Kamio
Yuji Kamio
JCJean-François Carrier
Jean-François Carrier
PWPhilip Wong
Philip Wong
TGThomas Gervais
Thomas Gervais
We describe the first microfluidic device for in vitro testing of brachytherapy (BT), with applications in translational cancer research. Our PDMS-made BT-on-chip system allows highly precise manual insertion of clinical BT seeds, reliable dose calculation using standard clinically-used TG-43 formalism and easy culture of naturally hypoxic spheroids in less than 3 days, thereby increasing the translational potential of the device. As the BT-on-chip platform is designed to be versatile, we showcase three different gold-standard post-irradiation bioassays and recapitulate, for the first time on-chip, key clinical observations such as dose rate effect and hypoxia-induced radioresistance. Our results suggest that BT-on-chip can be used to safely and efficiently integrate BT and radiotherapy to translational research and drug development pipelines, without expensive equipment or complex workflows.

8 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ERElena Refet-Mollof
Elena Refet-Mollof
RCRochin Chermat
Rochin Chermat
JLJulie Lafontaine
Julie Lafontaine
DYDavid (Run Zhou) Ye
David (Run Zhou) Ye
TGThomas Gervais
Thomas Gervais
PWPhilip Wong
Philip Wong
Background: Hypoxia influences the biology and response of tumors. Current methods to study hypoxia are low-throughput or use artificial induction, limiting the translational potential of findings. We previously described a user-friendly microfluidic chip to rapidly generate 240 large spheroids naturally harboring a hypoxic core. However, we had yet to validate the clinical relevance of these hypoxic-core (HyCo) spheroids, their use in understanding treatment resistance and their applications in targeted therapy testing. Methods: HyCo and small normoxic spheroids were generated on-chip from commercial and patient-derived soft-tissue sarcoma (STS) cell lines. Presence of hypoxia was validated through in silico modelling, immunofluorescence staining and RTqPCR. Whole-genome RNA sequencing was used to establish HyCo gene expression profile, compared to clinically-derived datasets, and used to identify target genes in hypoxic STSs. Apoptosis staining and clonogenic assay were used to evaluate HyCo therapy resistance to chemotherapy and radiotherapy. Matrigel invasion assay was used to quantify HyCo invasiveness and aggressivity. Diethyl-pythiDC was used to demonstrate the efficacy of P4HA1-inhibition on reducing HyCo invasiveness. Results: Large STSs spheroids generated on-chip naturally exhibit a diffusion-driven hypoxic core in only a few days. These HyCo spheroids recapitulate clinical hallmarks of hypoxia in STS: upregulation of hypoxia-related genes, resistance to chemotherapy/radiotherapy, and increased invasiveness. Our results suggest evidence of treatment resistance driven by hypoxia-induced paracrine signaling in STS. We identified P4HA1 gene as both upregulated in HyCo and prognostic in clinical STS and demonstrated that P4HA1-inhibition using diethyl-pythiDC reduced HyCo invasiveness. Conclusions: Our results demonstrate HyCo spheroids as efficient translational tools to integrate hypoxia in cancer research and drug development. We uncovered evidence of hypoxia-mediated chemoresistance in normoxic regions and successfully identified P4HA1-inhibition as a viable strategy for the treatment of hypoxic STSs, warranting further exploration.